Trial Profile

Phase II head-to-head trial comparing GZR18 with Semaglutide (Ozempic®) in Chinese T2DM patients

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bofanglutide (Primary) ; Semaglutide (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use

Most Recent Events

04 Jun 2025 New trial record
29 May 2025 According to a Gan & Lee Pharmaceuticals media release, company will present data from tis study at at the American Diabetes Association's 85th Scientific Sessions, and The study abstracts have been accepted for publication in Diabetes, the official journal of ADA, with the following presentations.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com